eligibility_summary
Adults 18–75 with consent and histologically confirmed locally advanced/metastatic salivary gland carcinoma, RECIST-measurable disease, ECOG 0–1, life expectancy ≥12 wks, adequate marrow/liver/renal/coagulation/urine protein, contraception/negative pregnancy test, arms by HER2/AR status (HER2-high, AR+, neither, HER2-low), follow-up compliance. Exclude recent malignancy/therapy, significant cardiac/QT issues, uncontrolled HTN, Arm2 oral absorption issues, GI bleed risk, or coagulopathy.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II, biomarker-assigned therapy for advanced salivary gland carcinoma. Arms/interventions and mechanisms: (1 & 4) SHR-A1811: anti-HER2 antibody–drug conjugate (ADC). Binds HER2 (ERBB2) on tumor cells, internalizes, and releases a cytotoxic payload to induce cell death, targets HER2-driven signaling (PI3K/AKT/MAPK) in HER2-high and HER2-low cohorts. (2) SHR-3680 (rezvilutamide): small-molecule androgen receptor (AR) antagonist blocking AR nuclear signaling, plus leuprolide: GnRH agonist suppressing pituitary LH/FSH and testosterone, achieving androgen deprivation. Together target AR-dependent tumor cells and the GnRH/LH–testosterone axis. (3) SHR-A1921: anti-TROP2 ADC delivering a cytotoxin to TROP2-expressing epithelial tumor cells, targets TROP2-mediated tumor cell populations in HER2−/AR− disease.